loading

Intensity Therapeutics Inc (INTS) 最新ニュース

pulisher
Mar 07, 2025

Tempest Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TPST - Benzinga

Mar 07, 2025
pulisher
Mar 05, 2025

Bile Duct Neoplasms Treatment Market Size Report 2032 | Taewoong - openPR

Mar 05, 2025
pulisher
Feb 21, 2025

Equillium (NASDAQ:EQ) Stock Quotes, Forecast and News Summary - Benzinga

Feb 21, 2025
pulisher
Feb 13, 2025

AMC Networks (AMCX) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail

Feb 13, 2025
pulisher
Feb 03, 2025

Intensity Infrastucture Partners Launches Open Season for New Natural Gas Transmission Pipeline to Serve the Bakken Region - Yahoo Finance

Feb 03, 2025
pulisher
Feb 03, 2025

Clinical Trials News Live Feed - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Xylem (XYL) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail

Feb 03, 2025
pulisher
Jan 28, 2025

Drug Monitoring Committee Authorizes Continuation of Intensity T - GuruFocus.com

Jan 28, 2025
pulisher
Jan 28, 2025

Intensity Therapeutics' sarcoma trial proceeds after review By Investing.com - Investing.com Canada

Jan 28, 2025
pulisher
Jan 28, 2025

Intensity Therapeutics' sarcoma trial proceeds after review - Investing.com India

Jan 28, 2025
pulisher
Jan 28, 2025

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review - Nasdaq

Jan 28, 2025
pulisher
Jan 28, 2025

High Intensity Focused Ultrasound Market Forecast and Company Analysis 2025-2033 Featuring Koninklijke Philips, Johnson & Johnson, Hitachi, General Electrics, Medtronic, Stryker, EDAP TMS, Theraclion - Yahoo Finance

Jan 28, 2025
pulisher
Jan 23, 2025

vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga

Jan 23, 2025
pulisher
Jan 21, 2025

Soft Tissue Sarcoma Market Poised for Significant Growth from - openPR

Jan 21, 2025
pulisher
Jan 15, 2025

Soft Tissue Sarcoma Pipeline Review 2024: Clinical Trials - openPR

Jan 15, 2025
pulisher
Jan 13, 2025

Alliance Global Partners Initiates Coverage of Intensity Therapeutics (INTS) with Buy Recommendation - MSN

Jan 13, 2025
pulisher
Jan 10, 2025

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 - PR Newswire

Jan 10, 2025
pulisher
Jan 10, 2025

Avoiding Isolation By Volunteering Offers Mental Health Benefits to Seniors - 69News WFMZ-TV

Jan 10, 2025
pulisher
Jan 06, 2025

Retrospective Analysis of Dosimetric Comparison Between Intensity-Modulated Radiation Therapy and Volumetric-Modulated Arc Therapy in Patients With Esophageal Cancer - Cureus

Jan 06, 2025
pulisher
Jan 01, 2025

Intensity Therapeutics stock hits 52-week low at $1.73 By Investing.com - Investing.com Australia

Jan 01, 2025
pulisher
Dec 31, 2024

Intensity Therapeutics stock hits 52-week low at $1.73 - Investing.com

Dec 31, 2024
pulisher
Dec 30, 2024

Internal Radiation Therapy - Market.us

Dec 30, 2024
pulisher
Dec 27, 2024

Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha

Dec 27, 2024
pulisher
Dec 24, 2024

Myelodysplastic Syndrome (MDS) Drugs Market Trends and - GlobeNewswire

Dec 24, 2024
pulisher
Dec 20, 2024

Intensity Therapeutics Stock Hits 52-Week Low at $1.76 By Investing.com - Investing.com Australia

Dec 20, 2024
pulisher
Dec 20, 2024

Intensity Therapeutics Stock Hits 52-Week Low at $1.76 - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Top pharma biotech companies R&D intensity globally 2023 - Statista

Dec 20, 2024
pulisher
Dec 13, 2024

Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance

Dec 13, 2024
pulisher
Dec 13, 2024

SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List - Yahoo Finance

Dec 13, 2024
pulisher
Dec 13, 2024

Intensity Therapeutics reports positive results of INT230-6 in breast cancer - Yahoo Finance

Dec 13, 2024
pulisher
Dec 13, 2024

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance

Dec 13, 2024
pulisher
Dec 13, 2024

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - Insider Monkey

Dec 13, 2024
$305.39
price down icon 0.49%
$34.30
price down icon 2.13%
$32.68
price down icon 0.56%
$19.19
price down icon 3.69%
$97.47
price down icon 2.86%
biotechnology ONC
$254.51
price up icon 1.87%
大文字化:     |  ボリューム (24 時間):